IL1RL2 and psoriasis: For example, in a mouse model of psoriatic inflammation induced by imiquimod (TLR7 agonist), the epidermal and skin features of psoriasis were strongly suppressed in IL-36R deficient mice and enhanced in IL36RN deficient mice, (Furue et al., 2018) suggesting that reducing IL-36 cytokines also had a potential role in therapy.